Thus, Fli-1 transactivating compounds may cooperate with Imatinib for the treatment of chronic myelogenous leukemia (CML) driven by BCR-ABL. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.